Portola Pharmaceuticals - Top 20 VC deals of 2008

Portola Pharmaceuticals, FierceBiotech top venture capital deals of 2008Company: Portola Pharmaceuticals
Based: South San Francisco, CA

Investors: Advanced Technology Ventures, Sutter Hill Ventures, Prospect Venture Partners, AllianceBernstein, Brookside International Incorporated, MPM Capital, D. E. Shaw Group, Frazier Healthcare and Technology Ventures, Ontario Teachers' Pension Plan, Industrial Bank of Taiwan, Alta Partners, T. Rowe Price Threshold Partnerships, Adage Inc., Pac-Link Management Corporation, Abingworth Management, CIDC Consultants, Goldman Sachs, Undisclosed Firm

Scoop: Portola is the only company to make both the 2007 and 2008 top 20 venture capital deals list. The company rounded up $60 million in July after securing $70 million in 2007. Most of the funding will help advance Portola's lead drug betrixaban, a therapy for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction and stroke. The money will support betrixaban through Phase II trials. Portola is also advancing its Phase I drug PRT060128 and additional preclinical targets.

Recently, Portola inked a $575 million deals that gave Novartis worldwide rights to Portola Pharmaceuticals' mid-stage anti-clotting therapeutic elinogrel.

Portola Pharmaceuticals - Top 20 VC deals of 2008

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.